Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 8 PART1, 2008, Pages 1292-1297

  Sawaki, Akira ^a   Kanemitsu, Yukihide ^a   Mizuno, Nobumasa ^a   Takahashi, Kuniyuki ^a   Nakamura, Tsuneya ^a   Ioka, Tatsuya ^a   Tanaka, Sachiko ^b   Nakaizumi, Akihiko ^b   Salem, Ahmed A S ^a   Ueda, Ryuzo ^c   Yamao, Kenji ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Gemcitabine; Pancreatic cancer; Prognostic index

Indexed keywords

C REACTIVE PROTEIN; FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASPIRATION BIOPSY; CANCER STAGING; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE REDUCTION; ENDOSCOPIC ECHOGRAPHY; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 48549106485     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04734.x     Document Type: Article

References (28)

1. Evans DB, Abbnrezzese JL, Willett CG. Cancer of the pancreas. In : De Vita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. Lippincott : Williams & Wilkins, 2001 1126 61.
2. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997 15 : 2403 13.
3. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999 85 : 1261 8.
4. Ziske C, Schlie C, Gorschluter M et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br. J. Cancer 2003 89 : 1413 17.
5. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958 53 : 157 81.
6. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 1966 50 : 163 70.
7. Cox DR. Regression models and life-tables. J. R. Stat. Soc. B 1984 34 : 588 91.
8. Harrell FE Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat. Rep. 1985 69 : 1071 7.
9. Harrell FE. S-plus Functions for Biostatistical/Epidemiological Modeling, Testing, Estimation, Validations, Graphics, Predicting and Typesetting, by Storing Enhanced Model Design Attributes in the Fit. Unix, Linus, and Microsoft Windows/NT versions. Pittsburg : Carnegie Mellon University, 1999. Cited October 2002. Available from: http://www.lib.stat.cmu.edu/
10. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York : John Wiley & Sons, 1990.
11. Moore MJ, Hamm J, Dancey J et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2003 21 : 3296 302.
12. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA, Marimastat Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 2001 19 : 3447 55.
13. Gastrointestinal Tumor Study Group. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. Ann. Surg. 1979 189 : 205 8.
14. Mohiuddin M, Cantor RJ, Biermann W, Weiss SM, Barbot D, Rosato FE. Combined modality treatment of localized unresectable adenocarcinoma of the pancreas. Int. J. Radiat. Oncol. Biol. Phys. 1988 14 : 79 84.
15. Whittington R, Neuberg D, Tester WJ, Benson AB 3rd, Haller DG. Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial. J. Clin. Oncol. 1995 13 : 227 32.
16. Treurniet-Donker AD, van Mierlo MJ, van Putten WL. Localized unresectable pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 1990 18 : 59 62.
17. Ueno H, Okada S, Okusaka T, Ikeda M. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000 59 : 296 301.
18. Terwee CB, Nieveen Van Dijkum EJ, Gouma DJ et al. Pooling of prognostic studies in cancer of the pancreatic head and periampullary region: the Triple-P study. Triple-P Study Group. Eur. J. Surg. 2000 166 : 706 12.
19. Falconer JS, Fearon KC, Ross JA et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995 75 : 2077 82.
20. Kalser MH, Barkin J, MacIntyre JM. Pancreatic cancer. Assessment of prognosis by clinical presentation. Cancer 1985 56 : 397 402.
21. Kau SY, Shyr YM, Su CH, Wu CW, Lui WY. Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers. J. Am. Coll. Surg. 1999 188 : 415 20.
22. Lacaine F, Fourtanier G, Fingerhut A, Hay JM. Surgical mortality and morbidity in malignant obstructive jaundice: a prospective multivariate analysis. Eur. J. Surg. 1995 161 : 729 34.
23. Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T. Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann. Surg. 2003 238 : 197 202.
24. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br. J. Surg. 2003 90 : 215 19.
25. Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 1998 89 : 1681 4.
26. Okada S, Okusaka T, Ishii H et al. Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn. J. Clin. Oncol. 1998 28 : 12 15.
27. Ishii H, Okada S, Nose H, Yoshimori M, Aoki K, Okusaka T. Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Pancreas 1996 12 : 267 71.
28. Cubiella J, Castells A, Fondevila C et al. Prognostic factors in nonresectable pancreatic adenocarcinoma: a rationale to design therapeutic trials. Am. J. Gastroenterol. 1999 94 : 1271 8.